GlassScriptPhysician profile
Victor Vazquez
NPI 1427266956
$8,851.43
in general payments reported to CMS, 2019-2025
36 companies · $1,630 in 2025
The $1,630 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $84.20 · 2021: $2,190 · 2022: $765 · 2023: $2,691 · 2024: $1,201 · 2025: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,581 · Consulting Fee: $1,798 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,580.82 |
| Consulting Fee | $1,798.16 |
| Education | $143.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,987.68 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Janssen Pharmaceuticals, INC | $803.32 | 2020-2025 | Darzalex, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $701.72 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Abbvie INC. | $366.62 | 2019-2025 | Epkinly |
| Amgen INC. | $323.01 | 2020-2024 | Lumakras, Xgeva, Vectibix |
| Karyopharm Therapeutics INC. | $202.40 | 2022-2025 | Xpovio |
| Janssen Biotech, INC. | $198.00 | 2021-2025 | Erleada |
| Merck Sharp & Dohme LLC | $196.47 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pfizer INC. | $185.76 | 2019-2024 | |
| Pbg Puerto Rico LLC | $160.10 | 2023-2025 | |
| Sobi, INC | $153.61 | 2024-2025 | |
| Immunogen, INC. | $129.95 | 2023-2024 | Elahere, Elahere |
| Rigel Pharmaceuticals, INC. | $125.00 | 2021 | |
| Genentech, INC. | $123.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.28 | 2023 | Iclusig, Ninlaro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $106.55 | 2023-2025 | |
| Genzyme Corporation | $102.12 | 2022-2025 | |
| Tempus Ai, INC | $95.13 | 2024-2025 | Xt Cdx |
| Eli Lilly Export S.A. Puerto Rico Branch | $93.32 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $79.08 | 2022-2024 | Columvi, Polivy, Lunsumio |
| Regeneron Healthcare Solutions, INC. | $72.99 | 2023-2025 | Libtayo |
| Exelixis INC. | $72.87 | 2022-2025 | Cabometyx |
| Gilead Sciences, INC. | $58.26 | 2023-2025 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $46.60 | 2024 | |
| Kite Pharma, INC. | $41.76 | 2019 | |
| Incyte Corporation | $39.04 | 2024-2025 | Monjuvi, Zynyz, Pemazyre |
| Seagen INC. | $38.22 | 2022 | |
| Glaxosmithkline, LLC. | $30.97 | 2021-2022 | |
| Eisai INC. | $30.00 | 2022 | |
| Caris Mpi, INC. | $27.88 | 2025 | Mi Cancer Seek |
| Bayer Puerto Rico INC. | $25.07 | 2025 | Nubeqa, Vitrakvi, Stivarga |
| Adaptive Biotechnologies Corporation | $24.08 | 2024 | Clonoseq |
| Stemline Therapeutics INC. | $23.89 | 2025 | Orserdu |
| Mirati Therapeutics, INC. | $23.31 | 2023 | Krazati |
| Astellas Pharma US INC | $20.64 | 2025 | Vyloy |
| Bayer Healthcare Pharmaceuticals INC. | $18.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.